CD133-directed CAR T-cells for MLL Leukemia: On-Target, Off-Tumor Myeloablative Toxicity by Bueno, Clara et al.
Leukemia
https://doi.org/10.1038/s41375-019-0418-8
LETTER
Immunotherapy
CD133-directed CAR T-cells for MLL leukemia: on-target, off-tumor
myeloablative toxicity
Clara Bueno1 ● Talia Velasco-Hernandez1 ● Francisco Gutiérrez-Agüera1 ● Samanta Romina Zanetti1 ●
Matteo L. Baroni1 ● Diego Sánchez-Martínez1 ● Oscar Molina1 ● Adria Closa2 ● Antonio Agraz-Doblás1,3 ●
Pedro Marín4 ● Eduardo Eyras2,5 ● Ignacio Varela 3 ● Pablo Menéndez1,5,6
Received: 16 October 2018 / Revised: 28 November 2018 / Accepted: 12 December 2018
© The Author(s) 2019. This article is published with open access
To the Editor:
Chimeric antigen receptors (CARs) have undoubtedly
revolutionized immunotherapy, especially in the B-cell
acute lymphoblastic leukemia (ALL) arena where over 80%
of complete remissions are observed in refractory/relapsed
(R/R) B-cell ALL patients treated with CD19-directed CAR
T-cells (CARTs) [1]. However, despite holding an unpre-
cedented promise, several issues still have to be resolved
before CARTs can be expanded to novel targets and/or
malignancies or even provided as ﬁrst-line treatment in B-
cell ALL [2]. For instance, toxicities such as cytokine
release syndrome and immune escape mechanisms includ-
ing loss of the antigen under CART-mediated pressure
remain major concerns, urging further research on the
mechanisms underlying CARTs cytotoxicity.
In this sense, loss of CD19 antigen is frequently observed
after CD19-directed CARTs therapy in B-cell ALL [3, 4],
but is particularly common in MLL-rearranged (MLLr) B-
cell ALL, an aggressive subtype of B-cell ALL (dismal in
MLL-AF4+ infants) associated with lymphoid-to-myeloid
lineage switch [3, 5, 6]. We read with interest the work
recently published in Leukemia by Li et al. reporting a
novel CAR targeting both CD19 and CD133 [7]. This study
proposes to use a bi-speciﬁc CAR targeting both CD19 and
CD133 antigens in a Boolean OR-gate approach for MLLr
B-cell ALL as a strategy to avoid and treat CD19- relapses.
The authors reasoned that CD133, encoded by PROM1
gene, is a speciﬁc marker for MLLr leukemia because
PROM1 is an MLL target, especially in MLL-AF4 B-cell
ALL [8–10]. They went on and performed in vitro assays
showing than CD19/CD133 bi-speciﬁc CAR triggers robust
cytotoxicity against CD19+ CD133+ and CD19-CD133+
B-cell lines [7], thus suggesting it may help in reducing
subsequent lineage switch in MLLr B-cell ALL.
A major drawback for CD133 as target in immu-
notherapy is its expression in hematopoietic stem and
progenitor cells (HSPCs), which would likely exert “on-
target off-tumor” myeloablative, life-threatening toxicity
[11, 12]. Because B-cell ALL is molecularly hetero-
geneous and can be diagnosed during infancy, childhood
and adulthood, we have characterized PROM1/CD133
expression in a large cohort of cytogenetically distinct B-
cell ALL subgroups (n= 212 patients) as well as in dif-
ferent subpopulations of normal CD34+ HSPCs obtained
across hematopoietic ontogeny from 22-weeks old human
fetal liver (FL, prenatal), cord blood (CB, perinatal), and
adult G-CSF-mobilized peripheral blood/bone marrow
(PB/BM, postnatal). An initial analysis of publicly
available RNA-seq data [13] from 170 diagnostic B-cell
ALL patients conﬁrmed that PROM1 is overexpressed in
patients with MLLr B-cell ALL, although its expression is
not signiﬁcantly higher than in other cytogenetic
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subgroups (Fig. 1a). We then analyzed PROM1 during
HSPC development and observed that PROM1 is highly
expressed in early normal hematopoietic stem cells (HSC)
and multipotent progenitors (MPP) with its expression
decreasing from the lymphoid-primed multipotent pro-
genitors (LMPP) onwards with its expression being mar-
ginal at later stages of myeloid differentiation
(megakaryocyte-erythroid progenitors, MEP) and
common lymphoid progenitors (CLP) [14] (Fig. 1b).
Importantly, 70% (22/32) of 11q23/MLLr B-cell patients
(both MLL-AF4 and MLL-AF9) express equal (9/32) or
lower (13/32) PROM1 levels that HSCs and MPPs, which
raises doubts about the suitability of PROM1 as a target
for B-cell ALL immunotherapy [15].
FACS clinical immunophenotyping provides a priori a
more rapid and feasible clinically relevant diagnostic
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Fig. 1 Characterization of CD133/PROM1 expression in B-cell ALL
and normal HSPCs. a Expression level of PROM1 in the indicated
cytogenetic subgroups of B-cell ALL (n= 170 patients at diagnosis)
determined by RNA-seq represented in log2(CPM) scale, with CPM
= counts per million [13]. b RNA-seq analysis comparing the
expression of PROM1 in 11q23/MLLr B-cell ALL (n= 29 patients)
with that in distinct fractions of Lin-CD34+ CD38-CD19- non-
lymphoid normal HSPCs (HSC hematopoietic stem cells, MPP mul-
tipotent progenitors, LMPP lymphoid-primed multipotent progenitors,
CMP common myeloid progenitors, GMP granulocyte-monocyte
progenitor, MEP megakaryocyte-erythroid progenitors) and in
common lymphoid progenitors (CLP) [14]. Data shown as normalized
counts. The boxes deﬁne the ﬁrst and third quartiles. The horizontal
line within the box represents the median. c Frequency (left) and mean
ﬂuorescence intensity (MFI, middle) of CD133+ BM blasts/cells in
MLLr (n= 7) and non-MLL B-cell ALLs (n= 5) primary diagnostic/
relapse samples or primografts (PDXs), and normal CD34+ HSPCs
derived from FL (n= 8), CB (n= 7) and adult PB/BM (n= 7).
Representative FACS dot plots for CD133 in normal CD34+ HSPCs
(upper right) and BM samples from two independent MLLr B-cell
ALL patients (bottom right)
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information than RNA-seq during the decision-making
process. Thus, we next FACS-analyzed the expression of
CD133 (PROM1 gene product) in the cell surface of BM-
derived primary blasts and primografts (PDXs) obtained
from 11q23/MLLr (n= 7) and non-MLL (n= 5) B-cell
ALL patients, and in comparison with healthy prenatal
(22 weeks old FL), perinatal (CB) and adult (PB/BM) CD34
+ HSPCs (Fig. 1c). Consistent with the RNA-seq data, the
expression of CD133 in 11q23/MLLr blasts is intermingled
with that observed in CD34+ HSPCs across hematopoietic
ontogeny (Fig. 1c).
Our data demonstrates that PROM1/CD133 is similarly
expressed between MLLr B-cell ALL primary blasts and
normal non-lymphoid HSPCs across ontogeny, thus indi-
cating that “on-target, off-tumor” toxic/myeloablative
effects are likely to occur if used in a bi-speciﬁc CAR
approach where CD133 antigen will be constantly targeted
regardless of the co-expression of CD19 in the same cell.
Our data therefore raises concerns about using CD133 as a
target for MLLr B-cell ALL immunotherapy. An alternative
to circumvent HSPC toxicity would be to engineer dual
CAR T-cells with one CAR engaging an antigen (i.e.,
CD19) mediating T-cell activation and another CAR
engaging a second antigen (i.e., CD133) mediating T-cell
co-stimulation [16]. Unfortunately, although such a CD19/
CD133 dual CAR might be likely safe due to its cytotoxi-
city being restrained only to cells co-expressing CD19 and
CD133, its speciﬁc cytotoxic performance will be poor
since not the entire MLLr B-cell ALL blast population is
CD19+CD133+ (Fig. 1c). Another alternative approach to
prevent HSPC toxicity would be to have in place a potent
molecular switch (i.e., iCas9) to eliminate CAR133-
expressing T-cells as necessary [17]. Further long-term
in vivo studies using both primary B-cell ALL cells and
normal HSCPs remain to be conducted to elucidate the
efﬁcacy versus the myeloablative toxicity of a CAR CD133
[18, 19].
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